Urokinase Antigen in Plasma of Patients with Liver Cirrhosis and Hepatoma

1985 ◽  
Vol 54 (03) ◽  
pp. 617-618 ◽  
Author(s):  
J C Kirchheimer ◽  
K Huber ◽  
P Polterauer ◽  
B R Binder
Keyword(s):  
Liver Cirrhosis ◽  
Liver Disease ◽  
Liver Function ◽  
Matched Control ◽  
Malignant Growth ◽  
Control Groups ◽  
Impaired Liver Function ◽  
Impaired Liver ◽  
Specific Medication ◽  
History Of

SummaryPlasma urokinase antigen levels were studied in 78 patients suffering from liver diseases. Blood was drawn before any specific medication was initiated. Impairment of liver function was comparable in all patients. In both groups of cirrhotic liver disease (alcoholic and non-alcoholic), normal levels of plasma urokinase antigen were found as compared to age-matched control groups. In both groups of patients with hepatomas (with or without a history of liver cirrhosis), however, significantly increased plasma urokinase antigen levels could be determined. These data indicate that an increase in plasma urokinase antigen might rather relate to malignant growth in liver disease than to impaired liver function.

scholarly journals HUBUNGAN KONSUMSI ALKOHOL DENGAN GANGGUAN FUNGSI HATI PADA SUBJEK PRIA DEWASA MUDA DI KELURAHAN TATELI DAN TELING ATAS MANADO

e-CliniC ◽  
2014 ◽  
Vol 2 (2) ◽  
Author(s):  
Dicky Conreng ◽  
B. J. Waleleng ◽  
Stella Palar
Keyword(s):  
Risk Factor ◽  
Liver Disease ◽  
Alcohol Consumption ◽  
Liver Function ◽  
Alcoholic Liver Disease ◽  
Impaired Liver Function ◽  
The Third ◽  
Impaired Liver ◽  
Keywords Alcohol ◽  
The World

Abstract: Alcohol consumption is the third biggest risk factor as a cause of disease and disability in the world, and is the biggest risk factor in America and second biggest in Europe as the cause of disease and disability. Alcohol is a causalfactorin 60 types of diseases and injuries and a component cause in 200 others. There are many diseases that is caused by alcohol consumption, one of them causes impaired liver function, such as alcoholic liver disease. However according to the theory, not all alcoholics will have an impaired liver function, so this reasearch was done to confirm that theory. Alcoholism will be measured by the AUDIT questionnaire and the impaired liver function will be measured by the increase in the GGT enzyme. Conclusion: Not all chronic alcoholics will have impaired liver function with the same amount of alcohol consumption. Keywords: alcohol, impaired liver function, alcoholic liver disease, AUDIT, GGT.     Abstrak: Konsumsi alkohol merupakan faktor risiko terbesar ketiga di dunia sebagai penyebab penyakit dan disabilitas, dan merupakan faktor risiko terbesar pertama di Amerika serta faktor risiko terbesar kedua di Eropa sebagai penyebab penyakit dan disabilitas. Alkohol merupakan faktor penyebab dari sekitar 60 jenis penyakit dan merupakan faktor komponen dari 200 jenis penyakit lainnya. Terdapat berbagai jenis penyakit yang disebabkan oleh konsumsi alkohol, salah satunya adalah gangguan fungsi hati seperti penyakit hati alkoholik (alcoholic liver disease). Namun menurut teori tidak semua peminum alkohol akan mengalami gangguan fungsi hati, sehingga penelitian ini dilakukan untuk memastikan teori tersebut. Gangguan konsumsi alkohol akan diperiksa menggunakan kuesioner AUDIT dan gangguan fungsi hati akan diperiksa melalui peningkatan enzim GGT. Simpulan: Tidak semua peminum alkohol kronik akan mengalami gangguan fungsi hati dengan jumlah konsumsi alkohol yang sama. Kata kunci: alkohol, gangguan fungsi hati, penyakit hati alkoholik, AUDIT, GGT.

Cholestasis is the Main Determinant of Abnormal CA 19–9 Levels in Patients with Liver Cirrhosis

2000 ◽  
Vol 15 (3) ◽  
pp. 226-230 ◽  
Author(s):  
E. Giannini ◽  
P. Borro ◽  
F. Botta ◽  
B. Chiarbonello ◽  
A. Fasoli ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Alkaline Phosphatase ◽  
Liver Cirrhosis ◽  
Liver Function ◽  
Univariate Analysis ◽  
Impaired Liver Function ◽  
Main Determinant ◽  
Clear Explanation ◽  
Impaired Liver ◽  
Cirrhotic Patients

Background/Aims Altered CA19–9 levels are commonly found in patients with liver cirrhosis though a clear explanation for this finding has not yet been given. The aim of this study was to investigate whether CA19–9 levels might be related to alterations in biochemical parameters and/or to functional impairment in cirrhotic patients with and without hepatocellular carcinoma. Methods: We studied 126 patients with liver cirrhosis, 60 of whom also had hepatocellular carcinoma. CA19–9 values were related to clinical, biochemical and functional parameters. In half of the patients CA19–9 levels were related to the monoethylglycinexylidide test, which is a dynamic liver function test. Results In more than half the cases CA19–9 values were above the upper limit. Liver function worsening as assessed by Child-Pugh's score and monoethylglycinexylidide test did not seem to influence the alteration of the marker. By contrast, in univariate analysis CA19–9 correlated with aminotransferases, γ-glutamyltransferase and alkaline phosphatase. Multivariate analysis showed that besides alkaline phosphatase also the presence of hepatocellular carcinoma might influence the alteration of CA19–9, although the marker was of no use for the diagnosis of liver cancer in patients with altered though not diagnostic α-fetoprotein levels. Conclusions In our study we confirmed the correlation of CA19–9 levels with cholestasis and cytolysis parameters. Moreover, we found no association between CA19–9 levels and impaired liver function as assessed by means of the Child-Pugh's score and the monoethylglycinexylidide test, which is cholestasis-independent and explores liver metabolic and clearance activities. The cholestatic picture that characterizes liver cirrhosis might enhance the expression and passage of the marker from the bile to the blood. The addition of CA19–9 assessment is not useful for the diagnosis of hepatocellular carcinoma in patients with non-diagnostic levels of α-fetoprotein. Caution should therefore be used when evaluating CA19–9 in cirrhotic patients with cholestasis, since false positive results may occur.

scholarly journals Use of drugs in children with impaired liver function

2020 ◽  
Vol 8 (3) ◽  
pp. 149-153
Author(s):  
Muzal Kadim
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Liver Function ◽  
Clinical Studies ◽  
The Body ◽  
Efficacy And Safety ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Impaired Liver Function ◽  
Liver Disorders ◽  
Impaired Liver

Liver disorders in children will affect the pharmacokinetics and pharmacodynamics of drugs that are metabolized in the liver. Chronic liver disease in children such as chronic hepatitis, cirrhosis of the liver can affect the absorption and disposition (pharmacokinetics) of drugs and the efficacy and safety (pharmacodynamics) of drugs in the body. Dosage modification is determined based on clinical studies examining the effects of impaired liver function on the pharmacodynamics and pharmacokinetics of a drug.

Outcomes following stereotactic body radiotherapy for patients with Child-Pugh B/C hepatocellular carcinoma.

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 167-167
Author(s):  
Shaelyn Culleton ◽  
Haiyan Jiang ◽  
Joon-Hyung J. Kim ◽  
James D. Brierley ◽  
Anthony M. Brade ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Disease ◽  
Liver Function ◽  
Median Survival ◽  
Stereotactic Body Radiotherapy ◽  
Liver Volume ◽  
Impaired Liver Function ◽  
Bridge To Transplant ◽  
Local Progression ◽  
Impaired Liver

167 Background: Assessment of outcomes in patients with hepatocellular carcinoma (HCC) and Child-Pugh B or C liver function treated with stereotactic body radiotherapy (SBRT). Methods: From 2004 – July 2012, 39 patients with HCC and Child-Pugh B/C liver function were treated with SBRT. Inclusion criteria included Child-Pugh B/C, treatment with SBRT, 5 to 15 fractions, and radical or palliative intent. Univariate analyses (UVA) were performed to assess relationships of patient demographics, liver function tests and treatment characteristics on overall survival (OS) and time to progression (TTP). Results: The majority of the 39 patients had Child-Pugh B7 liver function (69%), performance status ECOG 0-1 (82%), radiological evidence of tumor vascular thrombosis (62%) and hepatitis C as underlying liver disease (49%). 10 patients treated as bridge-to-transplant. The median dose was 3300 cGy in 6 fractions (range: 2000-4500 cGy in 5-15 fractions), individualized based on spared liver volume and underlying liver function. The median survival for all patients was 9.9 months (95% CI: 3.4-18.4). UVA demonstrated significantly reduced survival with Child-Pugh score > B7, baseline AFP > 1049 ng/mL (upper quartile) and gross tumor volume > 93 cm3. The median survival of patients treated with SBRT as a bridge-to-transplant versus the non-bridge-to–transplant patients was 30.7 months (95% CI: 0.6-not reached) versus 7.9 months (95% CI: 3.4-15.1; p=0.008). No HCC tumors treated with SBRT demonstrated local progression during the follow-up time. The median TTP for all patients was 18.8 months (95% CI: 6.2-not reached). Model for end stage liver disease (MELD) score > 12 was the only factor associated with reduced TTP on UVA. 31% of patients had a decline in Child-Pugh score by 2 or more points at 3 months. No acute treatment related toxicities of grade 3 or higher were reported. Conclusions: SBRT may be considered as a treatment option for HCC with impaired liver function. Survival is best in patients who are treated as a bridge-to-transplant, have smaller tumors, are Child-Pugh class B7, and have lower AFP levels. Randomized trials of radiation therapy in HCC patients with impaired liver function are warranted.

An unusual presentation of epigastric pain due to thrombophlebitis of a recanalised umbilical vein – case report

2019 ◽  
Vol 98 (8) ◽  
pp. 326-327 ◽  
Keyword(s):  
Liver Cirrhosis ◽  
Abdominal Pain ◽  
Case Report ◽  
Portal Hypertension ◽  
Liver Disease ◽  
Epigastric Pain ◽  
Umbilical Vein ◽  
History Of ◽  
Clinically Significant ◽  
Inflammatory Changes

Introduction: The umbilical vein can become recanalised due to portal hypertension in patients with liver cirrhosis but the condition is rarely clinically significant. Although bleeding from this enlarged vein is a known complication, the finding of thrombophlebitis has not been previously described. Case report: We report the case of a 62-year-old male with a history of liver cirrhosis due to alcoholic liver disease presenting to hospital with epigastric pain. A CT scan of the patient’s abdomen revealed a thrombus with surrounding inflammatory changes in a recanalised umbilical vein. The patient was managed conservatively and was discharged home the following day. Conclusion: Thrombophlebitis of a recanalised umbilical vein is a rare cause of abdominal pain in patients with liver cirrhosis.

scholarly journals A case of Hodgkin’s lymphoma with severely impaired liver function treated successfully with gemcitabine followed by ABVD

2015 ◽  
pp. 93 ◽  
Author(s):  
Rajshekhar Chakraborty ◽  
Shiva Kumar Reddy Mukkamalla ◽  
Garfield Gutzmore ◽  
Hon Cheung Chan
Keyword(s):  
Liver Function ◽  
Impaired Liver Function ◽  
Impaired Liver
Sign in / Sign up

Export Citation Format

Share Document